Prostatic Neoplasms Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Neoplasm,Prostatic / Neoplasms, Prostatic / Prostatic Neoplasm

Indication	Status	Phase
DBCOND0028225 (Prostatic Neoplasms)	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03007732	Pembrolizumab in Combination With Intratumoral SD-101 Therapy	Treatment	Abiraterone (DB05812) Leuprolide (DB00007) Pembrolizumab (DB09037) Prednisone (DB00635)